LUNG CANCER DIAGNOSTIC AND SCREENING MARKET ANALYSIS

Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others) Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy), By Cancer Type (Non-small cell lung cancer, Small Cell Lung CancerNeurosurgery), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023
Code : CMI4434
Pages :180
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Regional Analysis

Global Lung Cancer Diagnostic and Screening Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global lung cancer diagnostic and screening market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global lung cancer diagnostic and screening market is expected to witness significant growth in the coming years, driven by the high prevalence of lung cancer. The increasing prevalence of neurological disorders is contributing to the growth of the lung cancer diagnostic and screening market in the North America region. For instance, according to data published by the American Society of Clinical Oncology (ASCO) on March 3, 2023, worldwide, lung cancer is the second most commonly diagnosed cancer, while NSCLC (non-small cell lung cancer) is the most common type of lung cancer in the U.S., accounting for 81% of all lung cancer diagnoses.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa